AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)
(UPDATED Friday Oct. 2, 2020, 4:30 p.m. EDT)
Congressman Grills Novartis Executive About Steps to Limit 340B Discounts
A Republican U.S. congressman from rural central Pennsylvania yesterday questioned the head of drug manufacturer Novartis’ U.S. operations about the company’s plan to put conditions on 340B discounts on its products, during a hearing about Novartis’ and other companies’ “unsustainable drug prices.”